⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Time Course of Effectiveness of Two Rimegepant Dosing Regimens for the Prevention of Episodic Migraine (P10-15.008)

David Kudrow Andrew Charles Robert Fountaine Jeremias Antinew Patrizia de Besi Sergey Dubrovin Vittorio Loprinzo Terence Fullerton

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess how effective two different rimegepant dosing regimens are for preventing episodic migraines over time.
Evaluated two dosing regimens of rimegepant for migraine prevention.
Participants were individuals with episodic migraine.
Time course of effectiveness was monitored.
Both dosing regimens showed variation in effectiveness over time.
Specific outcomes based on time points were analyzed.

Implication

Trial evaluates effectiveness of two rimegepant dosing regimens for episodic migraine prevention, revealing time-dependent variations.

Abstract

To evaluate the time course of effectiveness of 2 rimegepant (RIM) regimens for the preventive treatment of episodic migraine.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kudrow et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055e22 https://doi.org/10.1212/wnl.0000000000215037

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Patient-reported Outcomes Through 12-weeks of Double-blind Rimegepant Treatment for the Prevention of Episodic Migraine in Adults with Prior Inadequate Response to Oral Preventatives (P1-15.008)Blinded Clinical Trial · 2026
2Post Hoc Analysis of Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mgOriginal Research · 2026
3Time Course of Rimegepant Effect for Acute Treatment of Migraine in Adults Unsuitable for Triptans: Exploratory Endpoints from a Phase 4, Randomized, Double-Blind, Placebo-Controlled StudyBlinded Clinical Trial · 2026
4Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraineMeta-Analysis · 2026 · 1 citations
5Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States2024 · 8 citations

More related papers

Efficacy and safety of rimegepant for acute and preventive treatment of migraine: a systematic review and meta-analysis of randomized controlled trials2026
Consistency of response to rimegepant for the acute treatment of migraine among real-world users – findings from the prospective observational CONFIDENCE study2026
Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics2024

More from Neurology

Role of APOE ɛ4 and ɛ2 With Longitudinal Cognitive Decline Among Those With Exceptional LongevityFri,
Associations of Antibodies Against Several Infections With Alzheimer Disease NeuropathologyFri,